Brief: Apontis Pharma H1 Adj. EBITDA At EUR 2.8 Mln

Apontis Pharma AG

11/08/2021 06:40

Aug 11 (Reuters) - APONTIS PHARMA AG  APPHG.DE :
    * APONTIS PHARMA BUILDS ON STRONG POSITION AND PROFITABILITY
IN
FIRST HALF OF 2021 - PRELIMINARY FIGURES AND FORECAST CONFIRMED
    * H1 ADJUSTED EBITDA 2.8 MILLION EUR
    * H1 EBITDA (ADJUSTED) INCREASES SIGNIFICANTLY BY EUR 4.3
MILLION
TO EUR 2.8 MILLION WITH ONLY DISPROPORTIONATELY LOW COST
DEVELOPMENT
    * H1 SINGLE PILLS REVENUES +83% TO EUR 14.0 MILLION AS A KEY
GROWTH DRIVER
    * FOR FINANCIAL YEAR 2021, MANAGEMENT BOARD CONTINUES TO
EXPECT
REVENUES OF EUR 48.5 MILLION AND EBITDA ADJUSTED OF EUR 5.5
MILLION

Source text for Eikon:  ID:nEQ3p13gWa 
Further company coverage:  APPHG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))